Recently, Huamu Medical, a biodegradable medical material and regenerative medicine company, completed tens of millions of yuan in Series C financing. This round of financing was led by Shenzhen High-tech Investment Capital, followed by Shanlan Capital, and Haoyue Capital acted as the exclusive financial advisor for this round of financing. This round of financing will be used to continue to promote the continuous research and development and clinical trials of the company’s absorbable and biodegradable products, as well as the commercialization of products . Previously, the company had invested in Tongchuang Weiye , Dynamic Balance, Hualing Capital, Dingxin Capital, Taiyu Capital and Yankuang Wenjing Fund.
Huamu Medical was established in Shanghai in 2016. It is mainly based on implantable degradable raw material technology, and its layout revolves around five major fields: sports medicine, spine, neuromaxillofacial, medical aesthetics, and ophthalmology, and it is applied in spinal surgery, trauma repair, and sports medicine. , neurosurgery, maxillofacial surgery, ophthalmology, medical aesthetics, synthetic biology and other fields, develop innovative degradable biomaterials with independent intellectual property rights and a variety of regenerative medicine products.
Biomedical materials are an interdisciplinary composite high-barrier technical field, and breakthroughs in the research and development of the domestic upstream material industry chain have always been an urgent problem in the discipline industry. To this end, Huamu Medical starts from upstream materials, focuses on breaking through the technical barriers of biomedical materials, and develops high-end absorbable products that are more in line with clinical and patient needs. There is a global innovative absorbable self-locking intervertebral fusion device in the research pipeline , Domestically innovative absorbable interface screws, absorbable threaded anchors, absorbable craniomandibular fixation systems and other products. With the succession of composite absorbable interface screws, composite absorbable threaded anchors and other products on the market, the innovative application of the company’s material technology will increase the localization rate in the upstream and downstream fields of materials, and break through the fields of sports medicine, spine, and neuroscience. Import monopoly situation in foreign fields.
According to the “2020-2027 Global Medical Implant Market Analysis and Industry Forecast” published by Allied Market Research, the global medical implant market in 2019 was 85.38 billion US dollars, and it is expected to reach 147.46 billion US dollars by 2027. The application of implants has gradually expanded from cardiovascular, neurointervention, traditional orthopedics, to sports medicine, spine, neurosurgery, medical aesthetics, and ophthalmology. The market space is huge and is still developing rapidly.
With the continuous development of biomedical materials, implant products have evolved from metal materials to polymer materials, but these materials cannot complete biological fusion and bone fusion. At the same time, metal fixation materials need to be implanted, which is a foreign body sensation for patients. Obviously, it brings secondary harm to the patient. Therefore, composite polyester materials that can absorb and promote regeneration have become the development trend of implants. This type of material can degrade in the human body, have better bone and tendon healing, and the operation is more minimally invasive and the recovery time is shorter.
It is understood that the current absorbable material products represented by Smith & Nephew and Johnson & Johnson still have problems such as unstable degradation rate and poor toughness. In this regard, Huamu Medical’s self-reinforced polylactic acid composite material processing technology has the advantages of degradation speed more in line with bone growth requirements, strength close to mainstream non-absorbable materials, and light tissue reaction.
Luo Yuxing, general manager of Huamu Medical, said that absorbable regenerative biomaterials are the field with the greatest value and the highest technical barriers in the field of medical devices. It is the only way to upgrade and iterate traditional materials, and represents the development trend of technology and clinical applications ; With the platform technology of absorption and regenerative medicine as the core, dozens of pipeline products have been developed, including implants, equipment, surgical instruments and other complete systems. In the next three years, more than ten new products of absorbable and regenerative medicine will be certified successively, for Subsequent commercialization brings unlimited possibilities; the company will also cover key tertiary hospitals according to the medium and long-term plan, and at the same time carry out market sinking layout.
media reports
Arterial Network Arterial Network Yiou 36Kr Investment Industry Entrepreneurship State
related events
- “Huamu Medical” completed the C round of financing of tens of millions of yuan, and Shenzhen Gaoxin Investment Capability invested2023-01-03
- Punce Medical completed the A-round financing of tens of millions of yuan2022-09-29
- Parkview Medical received A+ round of financing2022-08-24
- “Comet New Materials” received hundreds of millions of yuan in financing to accelerate the research of new heat dissipation materials2022-07-15
- Haimai Medical has completed tens of millions of angel round financing, and Huafang Capital is the exclusive investment2022-06-30
This article is transferred from: https://readhub.cn/topic/8mgzyxtOtbo
This site is only for collection, and the copyright belongs to the original author.